3D Systems announced that it completed the acquisition of Simbionix, a global leader in 3D virtual reality surgical simulation and training for $120 million in cash. The combination of Simbionix’s leading 3D surgical simulation and training tools with 3DS’ clinical capabilities in planning and instrumenting for complex personalized surgical procedures, 3D printed implants and patient-specific medical devices, accelerates the creation of a personalized healthcare platform that extends from the training room to the operating room. The company expects the acquisition to be immediately accretive to its cash generation and to its non-GAAP earnings per share.
“The acquisition of Simbionix extends our first mover advantage in the fast growing field of 3D printing enabled personalized medicine,” said Avi Reichental, President and CEO, 3DS. “Simbionix brings powerful technology, products, channels and domain expertise that complement our healthcare offerings and enhance our seamless digital thread for patient-specific healthcare. From the training room to the operating room, we are developing the digital thread for personalized medicine.”
Headquartered in Cleveland, Ohio with a research and development center in Israel, Simbionix has pioneered patient-specific simulation with FDA-cleared solutions that are changing how doctors prepare for individual surgeries. The company’s products include 16 simulation platforms with 60+ interventional procedures across 8 specialties, and can be found in simulation centers, hospitals, colleges and other educational facilities in over 60 countries.
Simbionix will operate under the continued leadership of Gary Zamler, CEO of Simbionix, who will become Vice President and General Manager, Simbionix Products for 3DS and immediately pursue synergistic integration opportunities leveraging the combined resources and expertise to advance 3DS’ healthcare portfolio further and faster.
